Wilsons Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2024
0mins
Source: Business Insider
Analyst Ratings: Shane Storey from Wilsons has maintained a Buy rating on Telix Pharmaceuticals Ltd. with a price target of A$22.00, while the stock currently trades at $14.51. The analyst consensus for the company is a Strong Buy with a price target of $16.49, indicating a potential upside.
Company Overview: Telix Pharmaceuticals is a clinical-stage biotechnology firm focused on developing targeted radiation therapies for prostate, renal, and glioblastoma cancers, operating in regions including Australia, the U.S., Belgium, and Japan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
